Metadate CD

Metadate CD is a brand name of methylphenidate, approved by the FDA in the following formulation(s):

METADATE CD (methylphenidate hydrochloride - capsule, extended release; oral)

• 
  Manufacturer: UCB INC
  
  Approval date: February 19, 2006
  
  Strength(s): 50MG, 60MG ^[RLD]

Has a generic version of Metadate CD been approved?

No. There is currently no therapeutically equivalent version of Metadate CD available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Metadate CD. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Methylphenidate modified release formulations
  Patent 6,344,215
  Issued: February 5, 2002
  Inventor(s): Marie J.; Bettman & Phillip J.; Percel & Dan L.; Hensley & Krishna S.; Vishnupad & Gopi M.; Venkatesh
  Assignee(s): Eurand America, Inc.
  A pharmaceutical MR (modified release) multiparticulate dosage form such as a capsule (once-a-day MR Capsule) of Methylphenidate indicated for the treatment of children with attention deficit hyperactivity disorder (ADHD), capable of delivering a portion of the dose for rapid onset of action and the remainder of the dose in a controlled manner for about 12 hours, is composed of a multitude of multicoated particles made of two populations of drug layered beads, IR (immediate release) and ER (extended release) Beads. The IR beads preferably are made by layering an aqueous solution comprising a drug and a binder on to non-pareil sugar spheres and then applying a seal coat to the drug coated cores. The ER Beads are made by applying an extended release coating of a water insoluble dissolution rate controlling polymer such as ethylcellulose to IR Beads. The MR Capsules are manufactured by filling IR and ER Beads in a proper ratio; the dose and the ratio required for an efficacious, cost effective and patient compliant treatment of children with ADHD were determined from extensive clinical investigations and in vitro- in vivo correlations performed as per FDA Guidelines, Guidance for Industry: Extended Release Oral Dosage Forms.
  
  Patent expiration dates:
  
  
  • October 27, 2020
    
    ✓ 
    Drug product
  
  

See also...

• Metadate CD Controlled-Release Capsules Consumer Information (Wolters Kluwer)
• Metadate CD Consumer Information (Cerner Multum)
• Metadate CD Advanced Consumer Information (Micromedex)
• Methylphenidate Consumer Information (Drugs.com)
• Methylphenidate Consumer Information (Wolters Kluwer)
• Methylphenidate Chewable Tablets Consumer Information (Wolters Kluwer)
• Methylphenidate Controlled-Release Capsules Consumer Information (Wolters Kluwer)
• Methylphenidate Controlled-Release Tablets Consumer Information (Wolters Kluwer)
• Methylphenidate Extended-Release Capsules Consumer Information (Wolters Kluwer)
• Methylphenidate Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Methylphenidate Solution Consumer Information (Wolters Kluwer)
• Methylphenidate System Consumer Information (Wolters Kluwer)
• Methylphenidate Consumer Information (Cerner Multum)
• Methylphenidate transdermal Consumer Information (Cerner Multum)
• Methylphenidate Oral, Transdermal Advanced Consumer Information (Micromedex)
• Methylphenidate Transdermal Advanced Consumer Information (Micromedex)
• Methylphenidate Hydrochloride AHFS DI Monographs (ASHP)